Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
Adicet Bio's experimental CAR-T therapy sparks early lupus remissions, drawing widespread industry attention.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Adicet Bio announced positive safety and efficacy data from its study of Prula-cel in patients with systemic lupus erythematosus with or without lupus nephritis. Following these findings, Wedbush raised its stock price target for the company.
Epilogue added 36d ago, after coverage quieted.
The brief
Recent coverage highlights significant developments surrounding Adicet Bio and its investigational treatment, prula-cel, formerly known as ADI-001. According to reports from multiple outlets, the company announced positive safety and efficacy data from a clinical study evaluating the therapy in patients suffering from systemic lupus erythematosus, both with and without lupus nephritis. The data specifically point toward encouraging signs of lupus remissions, which reporting describes as a potential new era for addressing autoimmune treatment approaches. Financial markets and media platforms quickly responded to the data release. Outlets including Investing.com India noted that Wedbush raised its stock price target for Adicet Bio following the trial disclosures.
Stock Titan coverage previously indicated that data concerning this potential lupus treatment were formally due on a Monday, coinciding with the timing of the announcement. Yahoo and Fierce Biotech further detailed the findings, characterizing the therapy as an off-the-shelf CAR-T option that shows distinct promise in combating the disease. Background context provided across the coverage focuses on the innovative nature of off-the-shelf CAR-T platforms and their application outside oncology, moving directly into autoimmune conditions like systemic lupus erythematosus. While standard treatments manage symptoms, the introduction of cellular therapies aims for deeper, more durable responses. The transition of prula-cel from its earlier designation as ADI-001 marks a specific developmental milestone that analysts and investors have closely monitored throughout the evaluation phase.
Looking forward, current reporting does not yet specify the exact timeline for subsequent clinical trial phases or regulatory submissions. Observers and market analysts will continue to track how Adicet Bio advances the prula-cel program and whether subsequent patient cohorts corroborate the initial safety and efficacy signals. Readers must consult forthcoming company updates to determine how these early clinical findings translate into broader therapeutic availability.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 49d ago.
Quick answers
What is the name of the Adicet Bio therapy evaluated in the study?
The therapy is named prula-cel, formerly known as ADI-001.
Which financial institution raised its stock price target for Adicet Bio?
Wedbush raised its stock price target following the lupus trial data.
What specific condition were the trial patients diagnosed with?
Patients had systemic lupus erythematosus, with or without lupus nephritis.
Coverage (5)
- Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis The Daily Tribune News · 51d ago
- Wedbush raises Adicet Bio stock price target on lupus trial data Investing.com India · 51d ago
- Data on a possible lupus treatment are due Monday Stock Titan · 51d ago
- An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus Yahoo · 51d ago
- Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches Fierce Biotech · 51d ago
Topics
Related trends
Cellectis will shed 70% of workforce as part of in vivo pivot
Cellectis announces 70% workforce reduction and strategic pivot to in vivo gene editing as Q3 revenue drops to $14.8M.
What the Nvidia scandal means for the company's earnings next week
Upcoming Nvidia earnings reports spark market attention amid leadership transitions and corporate scrutiny.
Supermicro stock jumps as server maker lifts revenue forecast
Supermicro stock surges following an upbeat revenue forecast driven by robust artificial intelligence server demand.
Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down
Caribou Biosciences, a biotech firm co-founded by Nobel laureate Jennifer Doudna, is halting its pipeline and reducing staff amid potential closure.
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
Kyverna advances its cell therapy toward an FDA submission as new one-year durability data emerges.
Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
Bristol Myers Squibb stock rises as its blood cancer cell therapy succeeds in a mid-stage trial.